{"id":579381,"date":"2026-04-21T00:00:00","date_gmt":"2026-04-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0041-2026-biopharma-non-small-cell-lung-cancer-unmet-need-unmet-need-metastatic-nsclc-without-driver-mutations-us\/"},"modified":"2026-04-26T11:08:46","modified_gmt":"2026-04-26T11:08:46","slug":"unneon0041-2026-biopharma-non-small-cell-lung-cancer-unmet-need-unmet-need-metastatic-nsclc-without-driver-mutations-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0041-2026-biopharma-non-small-cell-lung-cancer-unmet-need-unmet-need-metastatic-nsclc-without-driver-mutations-us\/","title":{"rendered":"Non-Small-Cell Lung Cancer &#8211; Unmet Need &#8211; Unmet Need &#8211; Metastatic NSCLC without driver mutations (US EU)"},"content":{"rendered":"<p>First-line treatment for non-small-cell lung cancer <abbr data-abbreviation-entity=\"4917\" title=\"non-small-cell lung cancer\">(<\/abbr><abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy, depending on the level of <abbr title=\"programmed death-ligand 1\">PD-L1<\/abbr> expression. Regimens that use dual checkpoint blockade are also available, such as Opdivo + Yervoy (Bristol Myers Squibb and Ono Pharmaceutical), with or without platinum-based chemotherapy, and Imfinzi + Imjudo (AstraZeneca) plus platinum-based chemotherapy. Second- and later-line treatment options are limited and largely depend on the regimen used in the prior lines. Despite these treatment options, there is a need for more effective and diverse treatments for patients with <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> without driver mutations.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXW211297821 BCX0 round-bullets\">\n<li>Which attributes most influence physicians\u2019 decisions for metastatic <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> without driver mutations?<\/li>\n<li>How do key current therapies, such as Keytruda, perform on key treatment drivers and goals for this patient population?<\/li>\n<li>What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for metastatic <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> without driver mutations?<\/li>\n<\/ul>\n<p><strong>Product description <\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom.<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European medical oncologists fielded in February 2026.<\/p>\n<p><strong>Key companies:<\/strong> Merck &#038; Co., Bristol Myers Squibb, Ono Pharmaceutical, AstraZeneca, Roche \/ Genentech, Regeneron Pharmaceuticals.<\/p>\n<p><strong>Key drugs:<\/strong> Keytruda, Opdivo, Yervoy, Tecentriq, Imfizi, Libtayo.<\/p>\n<div>\n<p><strong>Key feature:<\/strong> Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-579381","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/579381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/579381\/revisions"}],"predecessor-version":[{"id":579451,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/579381\/revisions\/579451"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=579381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}